Stock Analysis·← Pickers

MDCX

Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd. Common Stock (MDCX) is currently in a range/mixed trend, above the 50-day MA but below the 200-day MA. RSI is at 50.0, with 1/3 trend checks passing.

Price
$0.39
+0.04 (+11.60%)
Day range
$0.36–$0.41
52wk $0.25–$3.35
Volume
2.3M
Avg
Trend score
1/3
Range / Mixed
RSI (14)
50.0
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

MDCX with MA50 and MA200

3.232.491.751.010.2708/0110/2701/2304/2007/16
MDCX2025-08-012026-07-16
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$0.36+9.06% vs price
MA200
$1.16-65.94% vs price
RSI (14)
50.0Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Valuation

MDCX valuation multiples (TTM)

P/E Ratio
P/S Ratio
P/B Ratio
EV/EBITDA
Valuation multiples are provided by Financial Modeling Prep when available.
Analyst Ratings

MDCX analyst consensus

Avg Price Target
High Target
Low Target
Analyst Coverage
Analyst ratings and price targets are provided by Financial Modeling Prep when available.
Chart Summary
Trend summary for MDCX

Medicus Pharma Ltd. Common Stock (MDCX) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $0.39, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 9.1% and below the 200-day moving average by 65.9%.

Momentum and stretch context

MDCX currently has an RSI reading of 50.0, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

This page is designed to help you quickly understand what the MDCX chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.

Sector
Healthcare
Industry
Biotechnology
CEO
Raza Bokhari
Employees
16
Market cap
$8.4M
Beta
-0.65
52-week range
$0.25 – $3.35
Dividend
No
Exchange
NASDAQ
Country
CA
IPO date
15 Nov 2024
ISIN
CA58471K2020
CUSIP
58471K202
Company profile data from Financial Modeling Prep. MDCX listed on NASDAQ.
Share dilution

MDCX shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2023Mar 2026
Shares outstanding (latest)
29.5M
Since Jun 2023
+267.0%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. MDCX12 data points from Jun 2023 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about MDCX

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.